Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial

Nature Medicine lists a randomized, double-blind, active-comparator-controlled phase 3 trial comparing oral small-molecule GLP-1RA safiglipron with dapagliflozin in type 2 diabetes. The feed item provides no further context, so no trial results can be reported.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.